A Phase II Trial of Sunitinib in Never-smokers With Lung Adenocarcinoma: Identification of Oncogenic Alterations Underlying Sunitinib Sensitivity
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Sunitinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- 16 Nov 2017 Planned End Date changed from 1 Dec 2017 to 1 Jan 2018.
- 10 Jun 2017 Biomarkers information updated
- 19 Jan 2017 Status changed from recruiting to active, no longer recruiting.